Lonza has announced the launch of a new DPI capsule portfolio called Capsugel Zephyr “to meet the growing need for customized solutions for optimal pulmonary drug delivery.” The new DPI capsules are customizable and can be made from a variety of “different polymers and compositions,” with “product customization services to help address the specific needs of inhalation drug products manufacturers,” the company said.
Lonza Pharma & Biotech VP R&D Stef Vanquickenborne commented, “Capsule-based DPI technology is quickly becoming the preferred DPI drug delivery platform for pulmonary delivery. It provides drug stability advantages, encourages patient compliance and is cost-effective to manufacture with various dose carrying capacity. With over 20 years of experience in manufacturing DPI- capsules, Lonza offers a uniquely customized portfolio of polymers to meet the growing need of inhalation DPI products for pulmonary drug delivery.”
VP Global Sales, Capsule Delivery Solutions Fabio Invernizzi added, “With the launch of the Capsugel Zephyr capsule portfolio, Lonza will offer full end-to-end solutions for capsule-based DPI products. Our specialized capsule technology provides our customers with the right solution to deliver optimal product performance for the pulmonary route; a testament to how patient-centricity and customer focus are at the heart of Lonza’s healthcare continuum.”
Capsugel was acquired by Lonza in 2017. Capsugel had previously acquired Bend Research, Powdersize, and Xcelience. Lonza acquired the company from KKR, which bought Capsugel from Pfizer in 2011.
Read the Lonza press release.
